Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Ph1 Open-Label Multicentre Study to Assess Safety, Tolerability, PK and Anti-tumor Activity of Tremelimumab /Tremelimumab With MEDI4736 in Japanese With Advanced Solid Malignancies or Tremelimumab in Japanese With Malignant Mesothelioma

NCT02141347 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02141347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02141347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Ph1 Open-Label Multicentre Study to Assess Safety, Tolerability, PK and Anti-tumor Activity of Tremelimumab /Tremelimumab With MEDI4736 in Japanese With Advanced Solid Malignancies or Tremelimumab in Japanese With Malignant Mesothelioma
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
May 22, 2014
Completion date
January 27, 2017
Enrollment
65 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

part a and b: advanced solid malignancies, part c: malignant mesothelioma